Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual MeetingBusiness Wire • 05/19/23
Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual MeetingBusiness Wire • 05/12/23
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/09/23
Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business UpdateBusiness Wire • 05/09/23
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023Business Wire • 04/20/23
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual MeetingBusiness Wire • 04/18/23
Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS NucleaseBusiness Wire • 04/13/23
Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks ConferenceBusiness Wire • 03/27/23
Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/09/23
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business UpdateBusiness Wire • 03/09/23
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023Business Wire • 03/02/23
Precision BioSciences Announces Senior Leadership Promotions and Organizational ChangesBusiness Wire • 02/24/23
Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual ConferenceBusiness Wire • 02/22/23
Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio MilestonesBusiness Wire • 01/09/23
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company's Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical CandidateBusiness Wire • 01/06/23
Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual MeetingBusiness Wire • 12/10/22
iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver DiseasesBusiness Wire • 11/30/22
Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/08/22
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 11/08/22
Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual MeetingBusiness Wire • 11/03/22
Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022Business Wire • 11/02/22